Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) nanoparticles directly from solution; biological nanoforming technology; and dosage forms of Nanoparticles. It also offers STARMAP, an AI platform predicts the performance of your molecule in Nanoform's technology. The company was founded in 2008 and is headquartered in Helsinki, Finland.
Frequently asked questions
What sector does NANOFORM FINLAND OYJ (4YL) operate in?
NANOFORM FINLAND OYJ belongs to the Healthcare sector and operates in the Biotechnology industry.
What is NANOFORM FINLAND OYJ (4YL) current stock price?
As of the latest data, NANOFORM FINLAND OYJ stock price is €0.66, with a previous close of €0.68. NANOFORM FINLAND OYJ lost -€0.02 in the last trading session, representing a -2.79% loss.
What is NANOFORM FINLAND OYJ (4YL) current market capitalization?
NANOFORM FINLAND OYJ market cap is approximately 56.86 million.
What is NANOFORM FINLAND OYJ (4YL) Earnings Per Share (EPS)?
The trailing EPS is -€0.16.
What is NANOFORM FINLAND OYJ (4YL) EBITDA?
NANOFORM FINLAND OYJ EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -2.92 million.
Does NANOFORM FINLAND OYJ (4YL) pay dividends?
No. NANOFORM FINLAND OYJ does not pay a dividend.
When is NANOFORM FINLAND OYJ (4YL) next earnings report?
NANOFORM FINLAND OYJ is expected to release its next earnings report on September 30, 2026.
What is NANOFORM FINLAND OYJ (4YL) beta (volatility) score?
NANOFORM FINLAND OYJ has a beta of 0.876, meaning its volatility is roughly in line with the market.
